DUBLIN, June 3, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Anticoagulants Market in the US 2016-2020" report to their offering.

The report forecasts the anti-coagulants market in the US to grow at a CAGR of 6.67% during the period 2016-2020.

A trend to look forward to would be new therapeutic uses for anti-coagulant drugs. Using anticoagulants for purposes other than the normal anticoagulation effects will widen the scope of the market and help in gaining higher revenues. Heparin and related drugs are widely used for their anticoagulant activities. However, it has been identified that heparin exhibits anti-inflammatory activities and prevents the metastatic spread of tumor cells. Heparin exhibits anti-inflammatory activity by neutralizing cationic mediators, inhibiting adhesion molecules, and inhibiting heparanase, all of which are involved in leukocyte recruitment into tissues. Similarly, research studies indicate that heparins acts as an inhibitor of cell adhesion and thereby elicit anti-metastatic activities.

According to the report, a key growth driver would be the growing prevalence of coagulation disorders. Anticoagulants are prescribed in conditions such as AF, DVT, pulmonary embolism, stroke, clotting disorders, heart attack, and renal diseases. Cardiovascular disorders, kidney disorders, and strokes are becoming more prevalent due to unhealthy lifestyles among individuals, including a lack of physical activity, excessive alcohol consumption, and smoking.

It is estimated that 900,000 people are affected each year by DVT or pulmonary embolism, and 60,000-100,000 individuals die of this condition in the US. They are a major cause of maternal and hospital deaths in the US. Heart diseases are the leading cause of death in the region, with an estimated 610,000 deaths reported every year.

Further, the report states that one challenge that could hamper market growth is the side effects associated with drugs.

Key vendors:

• Johnson & Johnson
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Sanofi
• Daiichi Sankyo

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Anticoagulants: An overview

PART 06: Reimbursement scenario

PART 07: Anticoagulant reversal agents

PART 08: Approved anticoagulants in US

PART 09: Anticoagulants pipeline portfolio

PART 10: Market landscape

PART 11: Market segmentation by ROA

PART 12: Market segmentation by drug class

PART 13: Market segmentation by application

PART 14: Market drivers

PART 15: Impact of drivers

PART 16: Market challenges

PART 17: Impact of drivers and challenges

PART 18: Market trends

PART 19: Vendor landscape

For more information visit http://www.researchandmarkets.com/research/5dvj9p/anticoagulants

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets